多发性骨髓瘤的BCMA向疗法:2024年ASH年会的最新更新
Huijian Zheng1, Huajian Xian2, Wenjie Zhang1
1Fujian Provincial Key Laboratory on Hematology, Fujian Institute of Hematology, Fujian Medical University Union Hospital, 29 Xinquan Rd, Fuzhou, 350001, China.
B细胞成熟抗原 (BCMA) 是多发性骨髓瘤 (MM) 的关键标. 最新的研究突出显示了抗体-药物联合体 (ADC),双特异性抗体 (BsAbs) 和用于MM治疗的CAR-T细胞疗法.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 免疫治疗是一种免疫疗法.
背景情况:
- B细胞成熟抗原 (BCMA) 是多发性骨髓瘤 (MM) 的主要治疗点.
- 针对BCMA的治疗方法代表了MM治疗策略的重大进步.
- 2024年美国血液学会 (ASH) 年会展示了BCMA指导治疗的新进展.
更多相关视频
05:32Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice
Published on: January 7, 2019
09:34Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
Published on: February 17, 2022
相关概念视频
Targeted Cancer Therapies
There are several types of targeted therapies against...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Tumor Immunotherapy
M-Cdk Drives Transition Into Mitosis
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
